Hydrogenology
Source-linked study record

Inhalation of hydrogen gas elevates urinary 8-hydroxy-2′-deoxyguanine in Parkinson’s disease

Hirayama M, Ito M, Minato T, Yoritaka A, LeBaron TW, Ohno K. · Medical Gas Research. 2018;8(4):144–149.

HumanInhaled H₂Published 2018Source checked
Study record, not medical adviceThis record reports what the source states. It is not medical advice and does not establish that molecular hydrogen is effective, safe or appropriate for any person.
Quick summary

Study at a glance

Evidence type

Human

Population or model

People with Parkinson's disease receiving stable levodopa treatment.

Intervention and dose

Nasal inhalation for 10 minutes twice daily for four weeks, followed by crossover after an eight-week washout. · The generator supplied 3.0–3.5% H₂ in mixed air at 2 L/min. The authors estimated that dilution by a 5 L/min minute ventilation produced approximately 1.2–1.4% inspired H₂.

Duration

10 minutes twice daily for four weeks per condition, with an eight-week washout.

Reported result

H₂ produced no significant effect on odor identification, UPDRS part I or UPDRS part II. Urinary 8-OHdG increased by 16% after H₂ (paired p=0.02), but order-stratified subgroups were not significant by ANOVA. The authors proposed hormesis as a hypothesis; the trial did not demonstrate a beneficial clinical effect.

Main limitation

Only 20 participants, short low-dose exposure, several endpoints and a biomarker increase whose proposed hormetic meaning remains unproven. Funding included Japanese ministries and AMED, the Hori Sciences and Arts Foundation and the Smoking Research Foundation; authors declared no conflicts.

Evidence and classification

What kind of evidence is this?

Evidence type

Human

Reported design

Randomized double-blind placebo-controlled crossover trial

Research topic

Parkinson’s disease

Administration form

Inhaled H₂

Information not yet classified

Some editorial classification fields are still pending. The source-reported outcomes and result are shown below; Hydrogenology does not infer a positive or negative signal from prose automatically.

Reported in the source

Methods

Population or model

People with Parkinson's disease receiving stable levodopa treatment.

Sample

20 patients: 8 men and 12 women; mean age 69±6.8 years. Ten received H₂ first and ten placebo first.

Duration

10 minutes twice daily for four weeks per condition, with an eight-week washout.

Intervention

Nasal inhalation for 10 minutes twice daily for four weeks, followed by crossover after an eight-week washout.

Hydrogen form

H₂ diluted in room air — H₂ as the experimental component, not Brown's gas.

Dose or H₂ specification

The generator supplied 3.0–3.5% H₂ in mixed air at 2 L/min. The authors estimated that dilution by a 5 L/min minute ventilation produced approximately 1.2–1.4% inspired H₂.

H₂ flow

Approximately 60–70 mL/min H₂, calculated from 3.0–3.5% of the reported 2,000 mL/min generator output.

O₂ delivered with H₂

Mixed room air was the carrier and placebo. No separate O₂ intervention was used; O₂ percentage and absolute O₂ flow in the device output were not reported.

Comparator

Placebo device delivering 2 L/min air through an identical nasal cannula.

Reported, not endorsed

Outcomes and reported result

Outcomes measured

Japanese odor identification, UPDRS parts I and II and urinary 8-hydroxy-2′-deoxyguanine normalized to creatinine.

Reported result

H₂ produced no significant effect on odor identification, UPDRS part I or UPDRS part II. Urinary 8-OHdG increased by 16% after H₂ (paired p=0.02), but order-stratified subgroups were not significant by ANOVA. The authors proposed hormesis as a hypothesis; the trial did not demonstrate a beneficial clinical effect.

Extraction completeness

The complete PMC article, crossover sequence, device output, inspired-concentration estimate, all clinical outcomes, oxidative marker analysis, funding and conflict declaration were checked; null clinical results are prominent.

A reported association, difference or mechanism is not automatically a clinical benefit.

Interpretation limits

Limitations and applicability

Main methodological cautions

Only 20 participants, short low-dose exposure, several endpoints and a biomarker increase whose proposed hormetic meaning remains unproven. Funding included Japanese ministries and AMED, the Hori Sciences and Arts Foundation and the Smoking Research Foundation; authors declared no conflicts.

Applies directly to

People with Parkinson's disease on stable levodopa under this short crossover protocol; it did not show improvement in the measured clinical features.

No single-study GRADE certainty rating is assigned. Read how records and evidence assessments are prepared.

Sources and status

Sources and record status

Identifiers

PMID: 30713666 · DOI: 10.4103/2045-9912.248264

Publisher access

Free full article on PubMed Central.

Extraction basis

PubMed metadata and complete PubMed Central article; full-text and article-status check completed 8 August 2026.

Last reviewed

10 August 2026

Help the next reader

Help people check the facts before they buy.

Hydrogenology keeps 665 source-checked records accessible without advertising or product promotion.

Support independent access
Help us correct the recordReport a discrepancy

Send the exact difference between this page and the linked source. The study reference is attached automatically.